Showing results (271-280 of 463) with videos related to

Sort By:
Pageof 47
Movement Disorders : Official Journal of the Movement Disorder Society|October 22, 2008
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristicsC Warren Olanow, Robert A Hauser, Joseph Jankovic, et al.
Movement Disorders Clinical Practice|October 27, 2018
Focal Muscle Vibration Improves Gait in Parkinson's Disease: A Pilot Randomized, Controlled TrialFilippo Camerota, Claudia Celletti, Antonio Suppa, et al.
Neuroscience Letters|May 12, 2009
Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAsLucia Gatta, Alessio Cardinale, Francesca Wannenes, et al.
The European Journal of Neuroscience|March 25, 2005
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosetsMahmoud M Iravani, Emilie Syed, Michael J Jackson, et al.
International Review of Neurobiology|August 14, 2017
Nonmotor Symptoms in Experimental Models of Parkinson's DiseaseNataliya Titova, Anthony H V Schapira, K Ray Chaudhuri, et al.
NPJ Parkinson'S Disease|July 21, 2017
Non-oral dopaminergic therapies for Parkinson's disease: current treatments and the futureK Ray Chaudhuri, Mubasher A Qamar, Thadshani Rajah, et al.
Experimental Brain Research|June 7, 2011
Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's diseaseIgnacio Obeso, Leonora Wilkinson, Enrique Casabona, et al.
European Journal of Pharmacology|December 16, 2014
The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosetsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, et al.
European Journal of Pharmacology|August 24, 2006
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsSarah Rose, Michael J Jackson, Lance A Smith, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 5, 2002
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopaMikko Kuoppamäki, Ghassan Al-Barghouthy, Michael Jackson, et al.
Pageof 47